Bioxytran (BIXT) EBIT Growth (1y) (2011 - 2026)
Bioxytran (BIXT) EBIT Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 8.32% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 19.82% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 145.20% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 10.14% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 269.85% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1,528.74% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 99.51% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -36.55% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -336.63% |
| 10 | Bioxytran | 2.47 Mn | 2.22 Mn | - | -192.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -275.25% |
| Dec 31, 2025 | -24.36% |
| Sep 30, 2025 | -43.27% |
| Jun 30, 2025 | 63.22% |
| Mar 31, 2025 | 33.89% |
| Dec 31, 2024 | 51.50% |
| Sep 30, 2024 | 64.87% |
| Jun 30, 2024 | 42.39% |
| Mar 31, 2024 | -3.86% |
| Dec 31, 2023 | 8.01% |
| Sep 30, 2023 | -7,027.70% |
| Jun 30, 2023 | -96.88% |
| Mar 31, 2023 | 8.41% |
| Dec 31, 2022 | -16.93% |
| Sep 30, 2022 | 102.60% |
| Jun 30, 2022 | 48.46% |
| Mar 31, 2022 | 51.50% |
| Dec 31, 2021 | -20.57% |
| Sep 30, 2021 | -378.16% |
| Jun 30, 2021 | -831.40% |